School Of Public Health 4
151. Differences Between Self-Reported and Objectivel Measured Hearing Loss at Age 61–63 Years: The Newcastle Thousand Families Birth Cohort
152. Case Report: Vesicular Toxicodermia Induced by the Scabies Mite Sarcoptes Scabiei
153. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
154. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
155. Norway’s Battery Electric Vehicles and Public Health- Findings From the Literature
156. May Measurement Month 2022: an analysis of blood pressure screening results from Kazakhstan
157. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
158. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
159. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
160. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
161. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study
162. General, Vaccination, Navigational and Digital Health Literacy of Students Enrolled in Different Medical and Health Educational Programs
163. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
164. The Combined Effect of Multisensory Stimulation and Therapist Support on Physical and Mental Health of Older Adults Living in Nursing Homes: Pilot Randomized Controlled Trial
165. Self-reported changes in alcohol and tobacco use during COVID-19: Findings from the eastern part of WHO European Region
166. Factors associated with being on antiretroviral treatment among people living with HIV in Almaty, Kazakhstan
167. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
168. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
169. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
170. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
171. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
172. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
173. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
174. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
175. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
176. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
177. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
178. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
179. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
180. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 A Systematic Analysis for the Global Burden of Disease Study 2019
181. Sociodemographic Factors Associated with Physical Functioning in Elderly Males and Females from Serbia: Population-Based Modeling Study
182. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
183. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
184. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
185. Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990–2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021
186. A global action agenda for turning the tide on fatty liver disease
187. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
188. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
189. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
190. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
191. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
192. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
193. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
194. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
195. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
196. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
197. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
198. Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study
199. Measuring the Commercial Determinants of Health and Disease: A Proposed Framework
200. Measuring the Commercial Determinants of Health and Disease: A Proposed Framework
1 2 3 4 5 6 8